Highlights of the TEMPO-3 Trial
Based on the results of the Phase 3 TEMPO-3 randomized clinical trial, several key findings emerge regarding the use of tavapadon as an adjunctive treatment to levodopa in Parkinson’s disease (PD). First, tavapadon achieved a statistically significant increase of 1.10 hours in daily ‘good-on-time’ (on-time without troublesome dyskinesia) compared to placebo. Second, the drug demonstrated a robust reduction in daily ‘off-time,’ with a mean reduction of 0.94 hours over the placebo group. Third, the safety profile was characterized as favorable, with most adverse events being mild to moderate, primarily consisting of nausea and dizziness. Finally, the study confirms the clinical viability of selective D1/D5 receptor agonism, providing a novel mechanistic pathway for managing motor complications in patients already receiving stable levodopa therapy.
Addressing the Challenge of Motor Fluctuations in Parkinson Disease
For decades, oral levodopa has remained the gold standard for managing the motor symptoms of Parkinson disease. However, the long-term use of levodopa is frequently complicated by the development of motor fluctuations and dyskinesia. As the disease progresses, the therapeutic window for levodopa narrows, leading to ‘off’ periods where symptoms return before the next dose, and ‘on’ periods that may be marred by involuntary movements (dyskinesia).
To manage these fluctuations, clinicians often turn to adjunctive therapies, including dopamine (D) agonists. Traditionally, available dopamine agonists—such as pramipexole and ropinirole—target the D2 and D3 receptor families. While effective in reducing ‘off’ time, these agents are often associated with significant side effects, including somnolence, peripheral edema, and impulse control disorders (ICDs), which are thought to be mediated by their preferential activation of D2 and D3 receptors, particularly in the mesolimbic pathways. There has long been a clinical need for an agonist that provides the motor benefits of dopamine stimulation while minimizing the neuropsychiatric and systemic adverse events associated with broad D2/D3 activation.
The Mechanistic Rationale: Why D1/D5 Selectivity?
In the complex architecture of the basal ganglia, dopamine receptors are divided into two main families: D1-like (D1 and D5) and D2-like (D2, D3, and D4). The D1 receptors are primarily expressed on the medium spiny neurons of the direct pathway, which facilitates movement. In contrast, D2 receptors are predominantly located in the indirect pathway.
Tavapadon is a novel, investigational, oral, once-daily, selective D1/D5 receptor partial agonist. By selectively targeting the D1/D5 receptors, tavapadon aims to provide a more targeted stimulation of the direct pathway. Theoretically, this approach could offer a more physiological restoration of motor function with a lower propensity for the side effects driven by D2/D3 stimulation. Furthermore, as a partial agonist, tavapadon may provide a more stable and predictable level of receptor activation, potentially reducing the risk of peak-dose dyskinesia compared to full agonists.
TEMPO-3: Study Design and Methodology
The TEMPO-3 trial was a phase 3, double-blind, placebo-controlled randomized clinical trial conducted across 148 sites in 14 countries. The study period spanned from September 2020 to February 2024, involving a rigorous screening process and a 27-week treatment duration followed by a 4-week safety follow-up.
Participants included 507 adults with Parkinson disease who were experiencing motor fluctuations despite receiving a stable dose of oral levodopa (minimum 400 mg daily). The mean age of the participants was approximately 65 years, with a mean disease duration of 6.7 years. At baseline, participants reported an average of 5.5 hours of ‘off-time’ per day.
Participants were randomized in a 1:1 ratio to receive either flexible-dose tavapadon (5–15 mg once daily) or a matching placebo as an adjunct to their existing levodopa regimen. The flexible dosing allowed clinicians to optimize the balance between efficacy and tolerability for each individual patient. The primary end point was the change from baseline to week 26 in total daily ‘good-on-time,’ defined as the sum of on-time without dyskinesia and on-time with non-troublesome dyskinesia, as recorded in patient diaries. The key secondary end point was the change from baseline in total daily ‘off-time.’
Efficacy Results: Improving ‘Good-On-Time’ and Reducing ‘Off’ Periods
The results of the TEMPO-3 trial were highly significant. For the primary endpoint, patients treated with tavapadon experienced a mean increase in daily ‘good-on-time’ of 1.70 hours, compared to an increase of 0.60 hours in the placebo group. This resulted in a treatment difference of 1.10 hours (95% CI, 0.60-1.70; P < .001). This improvement is clinically meaningful, as it represents more than an hour of additional functional mobility without the interference of troublesome involuntary movements.
Regarding the key secondary endpoint, tavapadon demonstrated a significant reduction in daily ‘off-time.’ The tavapadon group saw a reduction of 1.88 hours, while the placebo group saw a reduction of 0.93 hours. The treatment difference of -0.94 hours (95% CI, -1.48 to -0.41; P < .001) underscores the drug's efficacy in smoothing out the motor fluctuations that plague patients in the middle to late stages of PD. These results were consistent across various subgroups, suggesting that the benefits of tavapadon are robust across a broad patient population.
Safety and Tolerability Profile
Safety is a paramount concern when introducing adjunctive therapies in PD, particularly given the elderly nature of the population and the potential for polypharmacy. In TEMPO-3, tavapadon was generally well-tolerated. While a higher percentage of participants in the tavapadon group experienced at least one adverse event (AE) compared to the placebo group (71.7% vs. 55.1%), the vast majority of these events (93.2%) were classified as nonserious and were of mild to moderate severity.
The most common adverse events reported in the tavapadon arm (incidence ≥5%) were nausea (14.3%), dyskinesia (10.0%), and dizziness (7.6%). The incidence of dyskinesia is notable but expected with any dopaminergic agent that increases ‘on’ time. Importantly, the rates of severe AEs and discontinuations due to AEs were relatively low, suggesting that the flexible-dosing strategy effectively managed tolerability issues for most participants.
Expert Commentary and Clinical Implications
The TEMPO-3 trial is a landmark study as it provides the first Phase 3 evidence for the efficacy of a selective D1/D5 agonist in Parkinson disease. For years, the D1 receptor was considered a ‘difficult’ target for drug development due to challenges in achieving oral bioavailability and maintaining a favorable side effect profile. Tavapadon appears to have overcome these pharmacological hurdles.
From a clinical perspective, tavapadon offers a new tool for the neurologist’s armamentarium. Its once-daily dosing provides a significant advantage in terms of patient adherence compared to multi-dose regimens. Furthermore, the mechanistic distinction from D2/D3 agonists is vital. While the TEMPO-3 abstract does not detail the rates of impulse control disorders, the theoretical reduction in D3-mediated mesolimbic stimulation is a promising aspect that warrants further investigation in long-term safety studies.
Clinicians should consider tavapadon for patients who are beginning to experience ‘wearing-off’ symptoms but who may be sensitive to the side effects of traditional agonists or who prefer the convenience of once-daily administration. However, as with all dopaminergic therapies, monitoring for nausea and dyskinesia remains essential during the titration phase.
Conclusion
In conclusion, the TEMPO-3 randomized clinical trial successfully demonstrated that tavapadon, as an adjunctive therapy to levodopa, significantly improves motor control in patients with Parkinson disease experiencing motor fluctuations. By increasing ‘good-on-time’ and reducing ‘off-time’ with a manageable safety profile, tavapadon represents a clinically significant advancement in the management of PD. As the first selective D1/D5 agonist to reach this stage of clinical validation, it opens a new chapter in the targeted treatment of dopaminergic deficiency.
Funding and ClinicalTrials.gov
This trial was funded by Cerevel Therapeutics, which was acquired by AbbVie. The trial is registered at ClinicalTrials.gov with the identifier NCT04542499.
References
1. Fernandez HH, Isaacson SH, Hauser RA, et al. Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial. JAMA Neurol. 2026; doi:10.1001/jamaneurol.2026.xxxx.
2. Olanow CW, Stocchi F. Levodopa-induced motor complications: are they avoidable? Parkinsonism Relat Disord. 2013;19(3):273-278.
3. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.
4. Kieburtz K, Katz R, Olanow CW, et al. Tavapadon for the Treatment of Parkinson Disease. Movement Disorders Clinical Practice. 2021.
